Searched for
OHM LABS
IIT-incubated startup SustLabs aims for $100 million ARR in next five yearsSustLabs, founded by Kaushik Bose and Soumya Bhattacharya in 2016, provides an AI stack which makes energy meters smart which can sense and...- Ranbaxy shares jump on approval of generic drug DiovanRanbaxy should be able to generate $190 million of sales and an after-tax profit of $100 million during 180 days, said a research analyst.
- Ranbaxy may launch generic of Novartis’ Diovan in US soonThis launch, pending since September 2012 when Novartis lost patent protection, could happen as early as May, one of the people quoted abov...
- Ranbaxy a lost case? Investors better off selling the stockToansa is the key active pharmaceutical ingredients facility and an alert is likely to put further pressure on business at least in the sho...
- USFDA bars products from Ranbaxy's Toansa plant citing data integrity violationsThe USFDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.
- No relief for Ranbaxy in the near term: Five factsThe FDA said the drugmaker is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.
- Ranbaxy to suffer operating losses post USFDA ban: Surajit Pal, Prabhudas Lilladher"For the Ohm Labs to manufacture formulations, around 70% of the supplies came from the Toansa API plant. So that business would be impacte...
- Ranbaxy Q3 net loss at Rs 454 croreThe company’s forex loss was at Rs 360 crore compared with a gain of Rs 393 crore last year.
- Ranbaxy rallies 19%: Just another flash in the pan, say analystsHowever, analysts are not expecting the stock to continue with its uptrend as USFDA overhang remains.
- Ranbaxy hunts for FDA-okayed plants in IndiaThis move will ensure launch plans are not jeopardised following Mohali setback.
- Ranbaxy may shift key drug filings from Mohali to USConsidering its US facility is already running chock-a-bloc, analysts feel, the company may cherry-pick and transfer its first to file ANDA...
- Ranbaxy Laboratories bounces back after 30% fall on MondayRanbaxy Laboratories rallied over 6%, a day after the stock plunged a little over 30% on reports that USFDA has issued an import alert.
- US import alert on Ranbaxy; Mohali unit part of consent decreeThe health regulator added that as per the import alert the officials may detain at the US border drug products manufactured at Ranbaxy's M...
- Ranbaxy Labs rallies 60% since August, loses 35% in a day thanks to FDA: Time to book profits?Analysts at top brokerage firms have turned cautious on Ranbaxy after reports that the FDA has issued an import alert on the Mohali unit.
- Ranbaxy can only sell US-made Lipitor copyThe US Food and Drug Administration has allowed Ranbaxy to manufacture generic Lipitor at Ohm Labs facility in the US for American market.
- HDFC recommends 'sell' on Ranbaxy for target of Rs 230HDFC Securities has downgraded Ranbaxy Laboratories (RLL) from Hold to “Sell” with a price target of Rs 230 per share in its post-result up...
- Angel recommends 'Sell' on Ranbaxy LaboratoriesAngel Broking has recommended a sell rating for Ranbaxy Laboratories after a warning was issued against the company from US FDA for its Ohm...
- Ranbaxy Laboratories is over-priced: EmkayEmkay Global Financial Services is of the view that the warning to Ranbaxy Laboratories’ Ohm plant will sentimentally dampen its stock pric...
- Ranbaxy Laboratories may start operations in new plants this yearThe country's largest drug company by sales, is also expanding the US plant to mitigate the US drug regulator’s embargo on drugs made at tw...
- Ranbaxy up 3% on USFDA nod for migraine drugAmid the general weakness in the market, shares of Ranbaxy Laboratories bucked the trend after it received the US Food and Drug Administrat...
Load More
